Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company's research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and… Read more
Eurofins-Cerep SA (ALECR) - Net Assets
Latest net assets as of June 2025: €73.54 Million EUR
Based on the latest financial reports, Eurofins-Cerep SA (ALECR) has net assets worth €73.54 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€84.58 Million) and total liabilities (€11.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €73.54 Million |
| % of Total Assets | 86.95% |
| Annual Growth Rate | 7.75% |
| 5-Year Change | 104.32% |
| 10-Year Change | 379.25% |
| Growth Volatility | 31.3 |
Eurofins-Cerep SA - Net Assets Trend (2000–2024)
This chart illustrates how Eurofins-Cerep SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eurofins-Cerep SA (2000–2024)
The table below shows the annual net assets of Eurofins-Cerep SA from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €71.74 Million | +11.03% |
| 2023-12-31 | €64.61 Million | +13.50% |
| 2022-12-31 | €56.93 Million | +25.46% |
| 2021-12-31 | €45.38 Million | +29.23% |
| 2020-12-31 | €35.11 Million | +18.88% |
| 2019-12-31 | €29.53 Million | +17.37% |
| 2018-12-31 | €25.16 Million | +18.11% |
| 2017-12-31 | €21.31 Million | +22.05% |
| 2016-12-31 | €17.46 Million | +16.62% |
| 2015-12-31 | €14.97 Million | +13.74% |
| 2014-12-31 | €13.16 Million | -1.39% |
| 2013-12-31 | €13.35 Million | -4.22% |
| 2012-12-31 | €13.93 Million | +2.71% |
| 2011-12-31 | €13.57 Million | -0.49% |
| 2010-12-31 | €13.63 Million | -27.88% |
| 2009-12-31 | €18.90 Million | -11.96% |
| 2008-12-31 | €21.47 Million | -10.22% |
| 2007-12-31 | €23.92 Million | +69.34% |
| 2006-12-31 | €14.12 Million | -54.63% |
| 2005-12-31 | €31.13 Million | -2.86% |
| 2004-12-31 | €32.05 Million | +8.04% |
| 2003-12-31 | €29.66 Million | +1.16% |
| 2002-12-31 | €29.32 Million | +12.04% |
| 2001-12-31 | €26.17 Million | +118.66% |
| 2000-12-31 | €11.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eurofins-Cerep SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5069492300.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €50.69 Million | 70.66% |
| Common Stock | €75.66K | 0.11% |
| Other Comprehensive Income | €10.12 Million | 14.11% |
| Other Components | €10.85 Million | 15.12% |
| Total Equity | €71.74 Million | 100.00% |
Eurofins-Cerep SA Competitors by Market Cap
The table below lists competitors of Eurofins-Cerep SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Q2 Metals Corp.
OTCQB:QUEXF
|
$93.20 Million |
|
QUISITIVE TECH. SOL.
F:N0C
|
$93.23 Million |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
$93.24 Million |
|
Nextensa NV
BR:NEXTA
|
$93.24 Million |
|
CROSSJECT SA EO -10
F:74C
|
$93.17 Million |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
$93.15 Million |
|
TCM Group
CO:TCM
|
$93.11 Million |
|
The Phoenix Holdings Ltd.
TA:PHOE
|
$93.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eurofins-Cerep SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 64,614,656 to 71,740,048, a change of 7,125,392 (11.0%).
- Net income of 7,154,548 contributed positively to equity growth.
- Other comprehensive income increased equity by 191,182.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.15 Million | +9.97% |
| Other Comprehensive Income | €191.18K | +0.27% |
| Other Changes | €-220.34K | -0.31% |
| Total Change | €- | 11.03% |
Book Value vs Market Value Analysis
This analysis compares Eurofins-Cerep SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.99x to 1.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €6027.13 | €18000.00 | x |
| 2003-12-31 | €6136.33 | €18000.00 | x |
| 2004-12-31 | €6607.84 | €18000.00 | x |
| 2005-12-31 | €6290.36 | €18000.00 | x |
| 2006-12-31 | €2815.59 | €18000.00 | x |
| 2007-12-31 | €4766.21 | €18000.00 | x |
| 2008-12-31 | €4254.21 | €18000.00 | x |
| 2009-12-31 | €3747.82 | €18000.00 | x |
| 2010-12-31 | €2703.01 | €18000.00 | x |
| 2011-12-31 | €2689.73 | €18000.00 | x |
| 2012-12-31 | €2762.49 | €18000.00 | x |
| 2013-12-31 | €2627.17 | €18000.00 | x |
| 2014-12-31 | €2610.76 | €18000.00 | x |
| 2015-12-31 | €2967.74 | €18000.00 | x |
| 2016-12-31 | €3460.94 | €18000.00 | x |
| 2017-12-31 | €4502.75 | €18000.00 | x |
| 2018-12-31 | €4989.05 | €18000.00 | x |
| 2019-12-31 | €5855.40 | €18000.00 | x |
| 2020-12-31 | €6961.05 | €18000.00 | x |
| 2021-12-31 | €8995.88 | €18000.00 | x |
| 2022-12-31 | €11286.65 | €18000.00 | x |
| 2023-12-31 | €12810.20 | €18000.00 | x |
| 2024-12-31 | €14222.85 | €18000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eurofins-Cerep SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.97%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.68%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.17x
- Recent ROE (9.97%) is above the historical average (0.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 1.96% | 1.29% | 0.77x | 1.98x | €-961.90K |
| 2001 | 9.16% | 8.66% | 0.68x | 1.56x | €-220.10K |
| 2002 | 10.90% | 9.26% | 0.72x | 1.63x | €263.80K |
| 2003 | 1.55% | 1.35% | 0.67x | 1.73x | €-2.51 Million |
| 2004 | 8.62% | 5.38% | 0.80x | 1.99x | €-441.24K |
| 2005 | -21.50% | -12.65% | 0.63x | 2.69x | €-9.81 Million |
| 2006 | -119.92% | -32.06% | 0.69x | 5.41x | €-18.35 Million |
| 2007 | 38.12% | 29.12% | 0.50x | 2.61x | €6.76 Million |
| 2008 | -9.99% | -6.79% | 0.58x | 2.56x | €-4.29 Million |
| 2009 | -11.47% | -8.08% | 0.61x | 2.34x | €-4.06 Million |
| 2010 | -39.65% | -22.35% | 0.67x | 2.63x | €-6.77 Million |
| 2011 | -0.58% | -0.35% | 0.70x | 2.41x | €-1.44 Million |
| 2012 | 2.28% | 1.44% | 0.73x | 2.17x | €-1.08 Million |
| 2013 | -6.66% | -4.40% | 0.72x | 2.09x | €-2.22 Million |
| 2014 | -3.76% | -2.67% | 0.81x | 1.74x | €-1.81 Million |
| 2015 | 12.08% | 8.03% | 0.89x | 1.68x | €311.51K |
| 2016 | 14.24% | 10.61% | 0.90x | 1.49x | €740.32K |
| 2017 | 18.07% | 15.77% | 0.81x | 1.42x | €1.72 Million |
| 2018 | 15.33% | 15.16% | 0.72x | 1.40x | €1.34 Million |
| 2019 | 14.80% | 14.09% | 0.78x | 1.35x | €1.42 Million |
| 2020 | 15.88% | 17.07% | 0.71x | 1.31x | €2.07 Million |
| 2021 | 21.69% | 23.65% | 0.70x | 1.32x | €5.31 Million |
| 2022 | 20.24% | 24.20% | 0.67x | 1.25x | €5.83 Million |
| 2023 | 11.82% | 17.33% | 0.56x | 1.23x | €1.18 Million |
| 2024 | 9.97% | 17.68% | 0.48x | 1.17x | €-19.46K |
Industry Comparison
This section compares Eurofins-Cerep SA's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $7,428,559
- Average return on equity (ROE) among peers: -28.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eurofins-Cerep SA (ALECR) | €73.54 Million | 1.96% | 0.15x | $93.20 Million |
| KLEA HOLDING (ALKLH) | $6.19 Million | -45.35% | 1.09x | $35.25 Million |
| Predilife (ALPRE) | $-764.29K | 0.00% | 0.00x | $3.27 Million |
| Lumibird SA (LBIRD) | $16.86 Million | -39.85% | 2.25x | $238.73 Million |